MedPath

Melatonin Administration as an Adjuvant Therapy in Preterm Infants with Neonatal Jaundice

Phase 3
Recruiting
Conditions
eonatal jaundice.
Neonatal jaundice associated with preterm delivery
P59.0
Registration Number
IRCT20231210060317N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Gestational age 32-37 weeks
Serum bilirubin level below exchange transfusion threshold
Indirect hyperbilirubinemia
Postnatal age under 30 days

Exclusion Criteria

Underlying diseases and congenital anomalies in the neonate
Any signs of neonatal sepsis or other infections
Signs and risk factors of hemolysis
Acute or chronic respiratory diseases

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum bilirubin level (mg/dL). Timepoint: Serum bilirubin levels will be measured in both groups before the intervention (T0), on the first day (T1), and on the second day (T2) after the intervention. Method of measurement: Blood test.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath